Indeed, it was shown that KRAS mutants promote metabolic dysregulation in cancer cells [19] and that metformin selectively inhibits metastatic colorectal cancer with the KRAS mutation [20]. This evidence concerns the gene KRAS and metastatic colorectal cancer.